Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Tracking major trends and clinical research in acute coronary syndrome care
Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.
New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.

Seeds for weight loss recalled: FDA says they are a ‘highly toxic’ plant containing cardiac glycosides

The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides.

Statin use after a bleeding stroke linked to key risk reductions

The study’s authors examined data from more than 15,000 patients who had their first intracerebral hemorrhage from January 2003 to December 2021

healthcare value value-based care money dollar

First 10 drugs chosen by White House for Medicare price negotiations include blood thinners, heart failure meds

Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House.

Texas researchers receive $1.14M to develop first CVD drug of its kind

If successful, the group's first-in-class medication would be able to target inflammation in CVD patients before it even occurs.

Missed opportunities: Many high-risk patients still not taking aspirin to prevent CVD

Aspirin is known to be an effective, affordable way to prevent cardiovascular disease.

A complete list of the European Society of Cardiology (ESC) 2023 Congress late-breaking Hot Line sessions. #ESCCongress

ESC Congress 2023 to feature 30 late-breaking clinical trials

The European Society of Cardiology's annual meeting is scheduled for Aug. 25-28, 2023, in Amsterdam.

doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%.

FDA highlights importance of including heart rhythm risks on drug labels

The agency has shared a new draft guidance focused on the inclusion of information related to QTc interval prolongation.

Pharmaceutics

Tracking major trends and clinical research in acute coronary syndrome care

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Late-breaking cardiovascular drug trials took center stage at ACC.25

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science